Compare JPMorgan Ultra Short Income ETF (JPST) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.29 (market cap $42.48B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 5.8× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 47 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| JPST | SYRE | |
|---|---|---|
Market Cap | $42.48B | $7.35B |
Volume | 12,289,471 | 1,624,631 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $108.92 |
52-Week Low | $50.22 | $22.18 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.31 with minimal daily movement, reflecting its ultra-short bond strategy focused on capital preservation. The technical picture shows bearish momentum with RSI indicators mixed, while fundamental data remains limited for this income-focused ETF. Recent news highlights institutional positioning changes and ongoing investor interest in ultrashort bond strategies amid rate uncertainty.
JPST offers investors exposure to high-quality, short-duration bonds with regular dividend distributions. The fund faces competition from similar ultrashort ETFs and sensitivity to Federal Reserve policy changes. Current market conditions favor cash-alternative strategies, though expense ratios and active management performance remain key considerations for investors seeking yield with minimal risk.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
